Two logit models are estimated to explain merger and acquisition (M&A) activities in US food manufacturing using firm level data for public firms: a "target model" predicting the likelihood of a firm being targeted for M&A and a "takeover model" predicting the likelihood of a targeted firm being tak
Mergers and acquisitions in the pharmaceutical and biotech industries
β Scribed by Patricia M. Danzon; Andrew Epstein; Sean Nicholson
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 237 KB
- Volume
- 28
- Category
- Article
- ISSN
- 0143-6570
- DOI
- 10.1002/mde.1343
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
We examine the determinants and effects of M&A activity in the pharmaceutical/biotechnology industry using SDC data on 383 firms from 1988 to 2001. For large firms, mergers are a response to expected excess capacity due to patent expirations and gaps in a firm's product pipeline. For small firms, mergers are primarily an exit strategy in response to financial trouble (low Tobin's q, few marketed products, low cashβsales ratios). In estimating effects of mergers, we use a propensity score to control for selection based on observed characteristics. Controlling for merger propensity, large firms that merged experienced a similar change in enterprise value, sales, employees, and R&D, and had slower growth in operating profit, compared with similar firms that did not merge. Thus mergers may be a response to trouble, but they are not a solution. Copyright Β© 2007 John Wiley & Sons, Ltd.
π SIMILAR VOLUMES
## Abstract PublicComp spent a lot of money to acquire another company. It seemed well worth it, based on financial reports. But a few weeks later, the CEO learned about some unusual journal entries on the acquired company's booksβand some troubling letters from customers. How could this have been
## Abstract In Italy, there is a growing demand for social responsibility in mergers and acquisitions (M&As). Academic and newspaper articles are full of stories about M&As analyzed from the buyer's point of view. But this article looks at the other side of the storyβthe view of the stakeholders of